What do leaders of disease-specific advocacy organizations know about pharmacogenomics and biomarkers, anyway?

ISSN： 1741-0541

Source： Personalized Medicine, Vol.6, Iss.2, 2009-03, pp. : 171-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What do dental students know about trauma?

DENTAL TRAUMATOLOGY, Vol. 31, Iss. 6, 2015-12 ,pp. : 482-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

What do we actually know about the referral process?

By Perkins Peter

British Journal of General Practice, Vol. 62, Iss. 595, 2012-02 ,pp. : 70-70

Royal College of General Practitioners

Access to resources Recommend Favorite

What do we know about the safety of corticosteroids in rheumatoid arthritis?

By Ethgen Olivier de Lemos Esteves Frédéric Bruyere Olivier Reginster Jean-Yves

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1147-1160

Informa Healthcare

Access to resources Recommend Favorite

What Do We Know About Medication Errors in Inpatient Psychiatry?

By Grasso Benjamin C. Rothschild Jeffrey M. Genest Robert Bates David W.

Joint Commission Journal on Quality and Patient Safety, Vol. 29, Iss. 8, 2003-08 ,pp. : 391-400

Joint Commission Resources

Access to resources Recommend Favorite

What do we actually know about the referral process?

By Davies Peter Pool Roger Smelt Graham

British Journal of General Practice, Vol. 61, Iss. 593, 2011-12 ,pp. : 752-753

Royal College of General Practitioners

Access to resources Recommend Favorite